Form 4: Acrivon Therapeutics' Chief Legal Officer Acquires Stock Options
SEC Form 4 Filing
Mary Miller, Chief Legal Officer of Acrivon Therapeutics, acquires stock options for 15,616 shares of common stock.
Summary
- On April 1, 2025, Mary Miller, the Chief Legal Officer of Acrivon Therapeutics, Inc., acquired stock options for 15,616 shares of the company's common stock.
- The exercise price of these options is $1.68 per share.
- The options vest over time, with 25% vesting on April 1, 2026, and the remaining shares vesting in 36 equal monthly installments thereafter, contingent upon continuous service.
- The options expire on March 31, 2035.
- A power of attorney was executed on April 2, 2025, granting certain individuals the authority to act on behalf of Mary-Alice Miller in matters related to SEC filings.
Sentiment
Score: 6
Explanation: The document is a routine regulatory filing regarding stock option grants, which is generally neutral in sentiment. It reflects standard compensation practices.
Positives
- The grant of stock options to the Chief Legal Officer aligns her interests with those of the shareholders, incentivizing her to contribute to the company's long-term success.
Future Outlook
The document does not contain specific forward-looking statements regarding the company's future performance.
Industry Context
Stock option grants are a common practice in the biotechnology industry to attract and retain key personnel, aligning their interests with the company's long-term success.
Comparison to Industry Standards
- Stock option grants are a standard component of compensation packages for executives in publicly traded biotechnology companies.
- The vesting schedule and exercise price are typical for such grants, designed to incentivize long-term commitment and performance.
- Comparable companies like Arvinas or Relay Therapeutics also utilize stock options as part of their executive compensation packages.
Stakeholder Impact
- The stock option grant could have a minor positive impact on shareholder sentiment as it aligns executive interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 04/01/2025 | Date of stock option grant to Mary Miller. |
| 04/01/2026 | First vesting date for 25% of the stock options. |
| 03/31/2035 | Expiration date of the stock options. |
| 04/02/2025 | Date of execution of Power of Attorney. |
| 04/03/2025 | Date of signature on the Form 4 filing. |
Keywords
stock options, Form 4, Acrivon Therapeutics, insider trading, Mary Miller, Chief Legal Officer, beneficial ownership, SEC, power of attorney, vesting
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.